Topic summary

What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset

Compounds › Semaglutide STEP programme randomised trial SELECT trial type 2 diabetes Solved

This is a generated summary. It shows the 9 most-liked posts from a topic of 131, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.cabreraTL2 Solution21 Dec 2024#5

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

I would put this at better than even and not much better.

8 likes 19mo

q.zhao_qaTL3Quality assurance15 Jan 2025 · edited#28

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

30 likes 18mo

citation_indexTL2Member23 Jan 2025 · edited#36

n.villalobos, post #25: Adding the measurement that post #24 says would settle it. A request rather than an answer: could whoever has the primary source for published dose-response for semaglutide post it? I have seen the claim three times this month and each version had lost a qualifier. Go to post

That is a cleaner way of putting what I was circling around.

28 likes in reply to #25 18mo

a.asanteTL218 Feb 2025#68

Published dose-response for semaglutide is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.

31 likes 17mo

r.vukovicTL224 Feb 2025#76

Since published dose-response for semaglutide keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

29 likes 17mo

KLindqvistTL4 Moderator1 Mar 2025 · edited#83

m.oyelaran, post #44: I had written a reply contradicting post #40 and deleted it. Here is what survived. The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the… Go to post

Post #82 is the version of this I will quote in future. One addition.

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

28 likes in reply to #44 17mo

buffer_sheetTL3Regular19 Mar 2025#108

Okafor, post #40: Picking up post #37: that is the part I would want checked first. Published dose-response for semaglutide: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this. Go to post

Post #107 is the version of this I will quote in future. One addition.

Published dose-response for semaglutide came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

32 likes in reply to #40 16mo

y.ibarraTL221 Mar 2025#111

Post #110 is right about the mechanism and I think understates the practical bit.

An update on my earlier published dose-response for semaglutide post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.

32 likes 16mo

PharmNotes_WhitfieldTL4Pharmacist30 Mar 2025#124

m.ilunga, post #98: What I want from this published dose-response for semaglutide thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it. Go to post

Building on post #121 rather than restating it.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

28 likes in reply to #98 16mo

Read the full topic (131 posts)

This topic was referenced in

Molecular mass of semaglutide and why the figure differs between sources — does this still hold?Compounds › Semaglutide · 102 replies
Coming back to: Semaglutide in people without diabetes: what the evidence base looks likeCompounds › Semaglutide · 46 replies
Second pass at: Semaglutide and alcohol: what is actually documentedCompounds › Semaglutide · 19 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. A follow-up question about…	+73	79	2k	4mo
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…	+5	9	30k	8d
Comparing the STEP programme populations: who was actually enrolled Compounds › Semaglutide SELECT trial STEP programme semaglutide effect size Solved Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…		2	7.5k	2mo
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide effect size randomised trial SELECT trial STEP programme Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…	+1	5	11k	20mo
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…	+2	6	18k	17mo

Related topics — sharing the tags STEP programme, randomised trial, SELECT trial

Topic	Participants	Replies	Views	Activity
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues amylin analogues randomised trial effect size cagrisema Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. A question about Amylin and gastric emptying that I think has a…	+21	25	44k	5mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…	+109	124	31k	10mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Evidence › Journal club randomised trial risk of bias effect size number needed to treat Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…	+80	91	10k	11mo
Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues randomised trial On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Posting a small dataset on amylin and gastric emptying. It is mine, it…		2	50k	17mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…	+18	22	37k	8mo